Outcomes of liver transplantation for hepatopulmonary syndrome in patients with concomitant respiratory disease
© 2023 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd..
BACKGROUND & AIMS: Concomitant respiratory disease is a common finding in patients with hepatopulmonary syndrome (HPS). Among patients who underwent liver transplantation (LT) for HPS, we compared characteristics and outcome of patients with versus without concomitant respiratory disease.
METHODS: This single center retrospective observational study included patients with HPS who underwent LT between 1999 and 2020.
RESULTS: During the study period, 32 patients with HPS received a LT; nine (28%) with concomitant respiratory disease of whom one required a combined lung-liver transplantation. Patients with concomitant respiratory disease had higher PaCO2 (38 vs. 33 mm Hg, p = .031). The 30-day postoperative mortality was comparable, but the estimated cumulative probability of resolution of oxygen therapy after LT in HPS patients with versus those without concomitant respiratory disease was lower: 63% versus 91% at 12 months and 63% versus 100% at 18 months (HR 95% CI .140-.995, p = .040). In addition to the presence of concomitant respiratory disease (p = .040), history of smoking (p = .012), and high baseline 99mTcMAA shunt fraction (≥20%) (p = .050) were significantly associated with persistent need of oxygen therapy. The 5-year estimated cumulative probability of mortality in patients with concomitant respiratory disease was worse: 50% versus 23% (HR 95% CI .416-6.867, p = .463).
CONCLUSIONS: The presence of a concomitant respiratory disease did not increase the short-term postoperative mortality after LT in patients with HPS. However, it resulted in a longer need for oxygen therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Clinical transplantation - 38(2024), 1 vom: 16. Jan., Seite e15171 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koc, Özgür M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hepatopulmonary syndrome |
|---|
| Anmerkungen: |
Date Completed 03.02.2024 Date Revised 18.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ctr.15171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363892249 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363892249 | ||
| 003 | DE-627 | ||
| 005 | 20240418232325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ctr.15171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM363892249 | ||
| 035 | |a (NLM)37897208 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koc, Özgür M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of liver transplantation for hepatopulmonary syndrome in patients with concomitant respiratory disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND & AIMS: Concomitant respiratory disease is a common finding in patients with hepatopulmonary syndrome (HPS). Among patients who underwent liver transplantation (LT) for HPS, we compared characteristics and outcome of patients with versus without concomitant respiratory disease | ||
| 520 | |a METHODS: This single center retrospective observational study included patients with HPS who underwent LT between 1999 and 2020 | ||
| 520 | |a RESULTS: During the study period, 32 patients with HPS received a LT; nine (28%) with concomitant respiratory disease of whom one required a combined lung-liver transplantation. Patients with concomitant respiratory disease had higher PaCO2 (38 vs. 33 mm Hg, p = .031). The 30-day postoperative mortality was comparable, but the estimated cumulative probability of resolution of oxygen therapy after LT in HPS patients with versus those without concomitant respiratory disease was lower: 63% versus 91% at 12 months and 63% versus 100% at 18 months (HR 95% CI .140-.995, p = .040). In addition to the presence of concomitant respiratory disease (p = .040), history of smoking (p = .012), and high baseline 99mTcMAA shunt fraction (≥20%) (p = .050) were significantly associated with persistent need of oxygen therapy. The 5-year estimated cumulative probability of mortality in patients with concomitant respiratory disease was worse: 50% versus 23% (HR 95% CI .416-6.867, p = .463) | ||
| 520 | |a CONCLUSIONS: The presence of a concomitant respiratory disease did not increase the short-term postoperative mortality after LT in patients with HPS. However, it resulted in a longer need for oxygen therapy | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hepatopulmonary syndrome | |
| 650 | 4 | |a liver transplantation | |
| 650 | 4 | |a oxygen therapy | |
| 650 | 4 | |a respiratory disease | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Aslan, Devrim |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Matthijs |e verfasserin |4 aut | |
| 700 | 1 | |a Verbeek, Jef |e verfasserin |4 aut | |
| 700 | 1 | |a Van Malenstein, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a van der Merwe, Schalk |e verfasserin |4 aut | |
| 700 | 1 | |a Monbaliu, Diethard |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Verleden, Geert M |e verfasserin |4 aut | |
| 700 | 1 | |a Pirenne, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Nevens, Frederik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 38(2024), 1 vom: 16. Jan., Seite e15171 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:1 |g day:16 |g month:01 |g pages:e15171 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.15171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 1 |b 16 |c 01 |h e15171 | ||